Lung Cancer Clinical Trials in New York

Showing 421-440 of 691 trials

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

NCT02381314

The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7-H3 expressing cancers. The study will also evaluate what is the best dose of enoblituzumab to use when given with ipilimumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of enoblituzumab in combination with ipilimumab.

MelanomaNon Small Cell Lung Cancer

MacroGenics24 participantsStarted Mar 2015

Los Angeles, California, United States • New Haven, Connecticut, United States • Miami Beach, Florida, United States +7 more locations

COMPLETEDPhase 1< 1 mile

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

NCT00967577

The purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.

Kidney CancerHead and Neck CancerBreast Cancer+6 more

Weill Medical College of Cornell University20 participantsStarted Jul 2009

New York, New York, United States

TERMINATEDPhase 2< 1 mile

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

NCT00372073

A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).

Non-small Cell Lung Cancer

Cyclacel Pharmaceuticals, Inc.187 participantsStarted Aug 2006

Tucson, Arizona, United States • Fountain Valley, California, United States • New Port Richey, Florida, United States +17 more locations

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

Lung Cancer Trials in Other Cities

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Personal Resilience Empowerment Program Study

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Safety Study of MGA271 in Refractory Cancer

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Other Conditions in New York